53364-85-5

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-4-chloro-2-methylquinoline is used as an intermediate compound for the synthesis of various pharmaceutical products. Its unique chemical structure allows it to be a key component in the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Dye Industry:
In the dye industry, 6-bromo-4-chloro-2-methylquinoline is used as a building block for the creation of new dye molecules. Its chemical properties contribute to the development of dyes with specific color characteristics and improved stability, making it a valuable resource for the production of high-quality dyes.
Used in Research and Development:
6-Bromo-4-chloro-2-methylquinoline is used as a research compound in laboratories and chemical plants. Its unique structure and properties make it an essential tool for studying various chemical reactions and processes, as well as for the development of new materials and technologies. 6-BROMO-4-CHLORO-2-METHYLQUINOLINE plays a crucial role in advancing scientific knowledge and driving innovation in various fields.

InChI:InChI=1/C10H7BrClN/c1-6-4-9(12)8-5-7(11)2-3-10(8)13-6/h2-5H,1H3

Upstream product

• 103030-28-0 6-bromo-4-hydroxy-2-methylquinoline 
• 71940-33-5 3-(4-bromo-anilino)-crotonic acid ethyl ester 
• 112182-47-5 6-bromo-4-hydroxy-2-methylquinoline 
• 71940-33-5 ethyl 3-(4-bromophenylamino)but-2-enoate 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 1126485-28-6 4-[(2-aminophenyl)thio]-6-bromo-2-methylquinoline hydrochloride 
• 951625-89-1 C₁₀H₁₀BrN₃ 

Relevant academic research and scientific papers

Anticancer, antimicrobial activities of quinoline based hydrazone analogues: Synthesis, characterization and molecular docking

Based on the biologically active heterocycle quinoline, a series (18a-p) of quinoline hydrazone analogues were prepared, starting from 6-bromo/6-chloro-2-methyl-quinolin-4-yl-hydrazines. For all the newly synthesized compounds cytotoxic activities were carried out at the National Cancer Institute (NCI), USA, against full NCI 60 human cancer cell lines. Amongst all the tested compounds, nine compounds (18b, 18d, 18e, 18f, 18g, 18h, 18i, 18j, 18l) exhibited important anti-proliferative activity at 10 μM concentration and were further screened at 10-fold dilutions of five different concentrations (0.01, 0.1, 1, 10 and 100 μM) with GI50 values ranging from 0.33 to 4.87 μM and LC50 values ranging from 4.67 μM to >100j μM. Further, the mean values of GI50, TGI and LC50 of the most potent compound 18j were compared with the clinically used anticancer agents bendamustine and chlorambucil, revealed that the quinolyl hydrazones holds promise as a potential anticancer agents. Further all the newly prepared compounds were screened for their antimicrobial activity. All the quinolyl hydrazones displayed good to excellent antimicrobial activity with MIC values ranging from 6.25 to 100 μg/mL against the tested pathogenic strains. Molecular docking of the synthesized compounds into the active binding site of human DNA topoisomerase I (htopoI) was carried out to predict the binding mode to the DNA topoisomerase I inhibitors. Hopefully in future, compounds based on quinoline core could be used as a lead compounds for designing new anticancer agents.

INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION

The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4 and A are as defined herein. The present invention also relates to compos

Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent

The invention relates to Mycobacterium tuberculosis-thioredoxin reductase inhibitors, processes for the preparation thereof, drugs containing said compounds, and the use of said compounds for manufacturing drugs.

Synthesis and antimicrobial evaluation of some new quinaldine derivatives

A new series of quinoline derivatives incorporated to glycosides and biologically active heterocyclic moieties were synthesized starting with 6-bromo-4-hydroxyquinaldine (6-bromo-4-hydroxy-2-methylquino-line) compound 1. Some of the synthesized compounds were evaluated for their antibacterial and antifungal activities. Most of the tested compounds exhibited potential antibacterial activity against Gram-positive bacteria, the detailed synthesis, spectroscopic data, antibacterial and antifungal evaluation of the synthesized compounds are reported.

N1-{4-[(10S)-Dihydroartemisinin-10-oxyl]}phenylmethylene-N 2-(2-methylquinoline-4-yl)hydrazine derivatives as antiplasmodial falcipain-2 inhibitors

A series of N1-{4-[(10S)-dihydroartemisinin- 10-oxyl]}phenylmethylene-N2-(2-methylquinoline-4-yl) hydrazine derivatives 9a-9n possessing 4-quinolylhydrazone and artemisinin cores were herein synthesized and evaluated for their activities against cysteine protease falcipain- 2 of Plasmodium falciparum. The structures were clearly confirmed by elemental analysis, 1H NMR, and mass spectra. The pharmacological results indicated that all compounds showed excellent activity against recombinant falcipain-2 (IC50 = 0.15-2.28 μM). The best one of this series was compound 9d (IC50 = 0.15 μM). The molecular docking results showed that the compound 9d made close contact with the key active site of cysteine protease falcipain-2.

COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS

Disclosed are quinoline and quinazoline compounds which modulate the activity of the gated ion channels. Compounds that modulate these gated ion channels are useful in the treatment of diseases and disorders related to pain, inflammation, the neurological system, the gastrointestinal system and genitourinary system. Preferred compounds include quinoline or quinazoline derivatives substituted at the 4- position via N(H), C(O) or O moieties.

Neuropeptide Y antagonists

Quinoline and quinazoline derivatives can be used in the form of pharmaceutical preparations as Neuropeptide Y antagonists for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.